A Phase 1, Double Blind (Sponsor Open), Randomized, Placebo Controlled, Parallel Group, Oral Multiple Dose Trial To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF 03882845 In Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 24 Dec 2009
At a glance
- Drugs PF 3882845 (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions; Pharmacokinetics
- 24 Dec 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 24 Dec 2009 Actual patient number (10) added as reported by ClinicalTrials.gov.
- 05 May 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.